The use of Lipid-Lowering Agents in Southern Europe is on the rise, with an increasing number of people seeking medication to manage their cholesterol levels.
Customer preferences: One of the main reasons for the growing demand for Lipid-Lowering Agents is the changing dietary habits of people in Southern Europe. The region has traditionally been known for its Mediterranean diet, which is rich in healthy fats such as olive oil and fish. However, in recent years, there has been a shift towards a more Western-style diet that is high in processed foods and saturated fats. This has led to an increase in obesity rates and a corresponding rise in cholesterol levels.
Trends in the market: As a result of these dietary changes, there has been a significant increase in the number of people in Southern Europe who require medication to manage their cholesterol levels. This has led to a growing market for Lipid-Lowering Agents, with a range of different medications available to consumers. One of the key trends in the market is the increasing use of statins, which are a type of medication that work to lower cholesterol levels in the blood.
Local special circumstances: While the overall trend towards a more Western-style diet is driving the growth of the Lipid-Lowering Agents market in Southern Europe, there are also some local special circumstances that are having an impact. For example, in countries such as Italy and Spain, there is a strong cultural tradition of eating cheese and cured meats, which can be high in saturated fats. This has led to a higher prevalence of high cholesterol levels in these countries compared to other parts of Europe.
Underlying macroeconomic factors: The Lipid-Lowering Agents market in Southern Europe is also being driven by underlying macroeconomic factors. With an ageing population and rising healthcare costs, there is a growing focus on preventative medicine and managing chronic conditions such as high cholesterol. This has led to increased investment in research and development of new Lipid-Lowering Agents, as well as greater awareness and education around the importance of managing cholesterol levels through medication and lifestyle changes.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
